|
|
中药治疗病毒后间质性肺纤维化的系统性评价和Meta分析
|
Abstract:
目的：研究通过Meta分析的方法，对近年来运用中医药干预治疗病毒后间质性肺纤维化有效性以及安全性进行客观评价，以期为今后应用中医药治疗本病提供更多的循证依据。方法：计算机检索中英文数据库，时限均自建库起至2024年03月01日，经文献筛选、数据提取后，对纳入文献的结果及结论进行描述性分析，采用PRISMA声明对纳入研究的文献质量进行评价，应用AMSTAR 2量表对方法学质量进行评价，运用RevMan5.4进行Meta分析。结果：共纳入7篇文献，包含8个随机对照研究，包含临床治疗患者844例，其中试验组437例，对照组407例。与对照组相比，试验组(中药/中药联合西医常规治疗)临床症状改善[OR = 3.22, 95% CI (2.20, 4.72), P < 0.00001] [MD = ？0.79, 95% CI (？0.19, ？0.48), P < 0.00001]；肺部纤维化得到改善[MD = ？2.74, 95% CI (？4.09, ？1.38), P < 0.00001]。肺功能(DLCO)并没有改善，差异无统计学意义[MD = 3.29, 95% CI (？0.67, 7.25), P = 0.10]。1个研究报告了不良反应，主要症状为心悸、胃食管反流、口腔溃疡、腹泻，可自行缓解或消失。结论：当前证据显示，中药不论是汤剂还是中成药亦或是中药制剂，其治疗病毒后间质性肺纤维化，能够有效改善患者呼吸困难、喘息、憋气等临床症状，提高患者生活质量；延缓肺部纤维化的进展；暂未报告严重不良反应。但研究结论尚需更多标准严格、质量高、大样本的随机对照试验研究予以证实。
Objective: To objectively evaluate the effectiveness and safety of the intervention of Traditional Chinese Medicine (TCM) in the treatment of post-viral interstitial pulmonary fibrosis using meta-analysis, with the aim of providing more evidence-based support for the future application of TCM in treating this condition. Method: A computerized search was conducted in both Chinese and English databases, with the time limit extending up to March 1, 2024. Following literature screening and data extraction, a descriptive analysis of the results and conclusions of the included studies was performed. The quality of the included studies was evaluated using the PRISMA statement, and the methodological quality was assessed using the AMSTAR 2 tool. Meta-analysis was conducted using RevMan 5.4. Results: A total of 7 studies were included, comprising 8 randomized controlled trials with 844 clinical treatment patients, of which 437 were in the experimental group and 407 in the control group. Compared to the control group, the experimental group (TCM/TCM combined with conventional Western medicine treatment) showed significant improvement in clinical symptoms [OR = 3.22, 95%CI (2.20, 4.72), P < 0.00001] [MD = ？0.79, 95% CI (？0.19, ？0.48), P < 0.00001]; pulmonary fibrosis was also improved [MD = ？2.74, 95% CI (？4.09, ？1.38), P < 0.00001]. However, there was no significant improvement in lung function (DLCO), with no statistically significant difference [MD = 3.29, 95% CI (？0.67, 7.25), P =
| [1] | 李想, 常虹, 石松利, 等. 肺纤维化的中医病机及中医药治疗研究进展[J]. 中药药理与临床, 2021, 37(1): 240-247. |
| [2] | Raghu, G., Remy-Jardin, M., Myers, J.L., Richeldi, L., Ryerson, C.J., Lederer, D.J., et al. (2018) Diagnosis of Idiopathic Pulmonary Fibrosis. an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 198, e44-e68. https://doi.org/10.1164/rccm.201807-1255st |
| [3] | Balthesen, M., Messerle, M. and Reddehase, M.J. (1993) Lungs Are a Major Organ Site of Cytomegalovirus Latency and Recurrence. Journal of Virology, 67, 5360-5366. https://doi.org/10.1128/jvi.67.9.5360-5366.1993 |
| [4] | Ankermann, T., Claviez, A., Wagner, H., Krams, M. and Riedel, F. (2003) Chronic Interstitial Lung Disease with Lung Fibrosis in a Girl: Uncommon Sequelae of Epstein‐Barr Virus Infection. Pediatric Pulmonology, 35, 234-238. https://doi.org/10.1002/ppul.10244 |
| [5] | Sides, M.D., Klingsberg, R.C., Shan, B., Gordon, K.A., Nguyen, H.T., Lin, Z., et al. (2011) The Epstein-Barr Virus Latent Membrane Protein 1 and Transforming Growth Factor-β1 Synergistically Induce Epithelial-Mesenchymal Transition in Lung Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 44, 852-862. https://doi.org/10.1165/rcmb.2009-0232oc |
| [6] | 徐艳菊, 张翊玲, 路苹, 等. EB病毒感染对结缔组织病相关性间质性肺炎的影响研究[J]. 中国全科医学, 2020, 23(18): 2254-2258, 2265. |
| [7] | Saha, A., Vaidya, P.J., Chavhan, V.B., et al. (2018) Combined Pirfenidone, Azithromycin and Prednisolone in Post-H1N1 ARDS Pulmonary Fibrosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 35, 85-90. |
| [8] | Lu, P.X., Wang, Y.X., Zhou, B.P., et al. (2010) Radiological Features of Lung Changes Caused by Avian Influenza Subtype A H5N1 Virus: Report of Two Severe Adult Cases with Regular Follow-Up. Chinese Medical Journal, 123, 100-104. |
| [9] | 解立新, 刘又宁, 郝凤英, 等. 258例严重急性呼吸综合征康复期患者肺功能与影像学动态随访与分析[J]. 中华结核和呼吸杂志, 2004(3): 6-9. |
| [10] | Huang, L., Yao, Q., Gu, X., Wang, Q., Ren, L., Wang, Y., et al. (2021) 1-year Outcomes in Hospital Survivors with COVID-19: A Longitudinal Cohort Study. The Lancet, 398, 747-758. https://doi.org/10.1016/s0140-6736(21)01755-4 |
| [11] | Huang, L., Li, X., Gu, X., Zhang, H., Ren, L., Guo, L., et al. (2022) Health Outcomes in People 2 Years after Surviving Hospitalisation with COVID-19: A Longitudinal Cohort Study. The Lancet Respiratory Medicine, 10, 863-876. https://doi.org/10.1016/s2213-2600(22)00126-6 |
| [12] | 邵池, 蒋捍东, 张惠兰, 等. 新型冠状病毒感染引起的肺间质病变诊断和治疗专家建议[J]. 中华结核和呼吸杂志, 2020, 43(10): 827-833 |
| [13] | Balshem, H., Helfand, M., Schünemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., et al. (2011) GRADE Guidelines: 3. Rating the Quality of Evidence. Journal of Clinical Epidemiology, 64, 401-406. https://doi.org/10.1016/j.jclinepi.2010.07.015 |
| [14] | Guyatt, G.H., Oxman, A.D., Sultan, S., Glasziou, P., Akl, E.A., Alonso-Coello, P., et al. (2011) GRADE Guidelines: 9. Rating up the Quality of Evidence. Journal of Clinical Epidemiology, 64, 1311-1316. https://doi.org/10.1016/j.jclinepi.2011.06.004 |
| [15] | 何明, 张晓梅, 苑惠青, 等. 银杏叶提取物治疗SARS后肺间质纤维化的疗效与机理研究[J]. 中华中医药杂志, 2005, 20(12): 752-753. |
| [16] | 张梦云, 丁晓娟, 肖静静, 等. 养肺通络方辅助治疗新型冠状病毒感染后肺纤维化的回顾性分析[J]. 中医杂志, 2022, 63(23): 2252-2258. |
| [17] | 张纾难, 段军, 张志远, 等. 中西医结合治疗SARS所致肺纤维化61例疗效分析[J]. 中国医药学报, 2003, 18(10): 609-610. |
| [18] | 张丽霞, 张淑文. SARS恢复期肺纤维化中西医结合诊治的研究[J]. 中国中西医结合急救杂志, 2004, 11(5): 268-270. |
| [19] | 凡进, 张静. 研究西医联合益气宣痹汤治疗新冠肺炎后肺纤维化倾向可行性[J]. 世界最新医学信息文摘(连续型电子期刊), 2020, 20(73): 166-167. |
| [20] | 陈中沛, 李洁, 陈阳, 等. 培元通闭散结中药治疗新型冠状病毒肺炎恢复期肺纤维化的临床研究[J]. 世界科学技术-中医药现代化, 2023, 25(1): 380-386. |
| [21] | An, X., Duan, L., Zhang, Y.H., Jin, D., Zhao, S., Zhou, R.R., et al. (2021) The Three Syndromes and Six Chinese Patent Medicine Study during the Recovery Phase of COVID-19. Chinese Medicine, 16, Article No. 44. https://doi.org/10.1186/s13020-021-00454-x |
| [22] | George, P.M., Wells, A.U. and Jenkins, R.G. (2020) Pulmonary Fibrosis and COVID-19: The Potential Role for Antifibrotic Therapy. The Lancet Respiratory Medicine, 8, 807-815. https://doi.org/10.1016/s2213-2600(20)30225-3 |
| [23] | Zhang, C., Wu, Z., Li, J., Tan, K., Yang, W., Zhao, H., et al. (2020) Discharge May Not Be the End of Treatment: Pay Attention to Pulmonary Fibrosis Caused by Severe Covid‐19. Journal of Medical Virology, 93, 1378-1386. https://doi.org/10.1002/jmv.26634 |
| [24] | Dempsey, T.M., Payne, S., Sangaralingham, L., Yao, X., Shah, N.D. and Limper, A.H. (2021) Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 18, 1121-1128. https://doi.org/10.1513/annalsats.202007-901oc |
| [25] | 卫博凯, 胡静. 基于中医传承辅助平台与网络药理学探析中药干预新型冠状病毒感染后遗症肺纤维化的作用机制[J]. 中草药, 2024, 55(1): 190-204. |
| [26] | Wang, Y., Sang, X., Shao, R., Qin, H., Chen, X., Xue, Z., et al. (2022) Xuanfei Baidu Decoction Protects against Macrophages Induced Inflammation and Pulmonary Fibrosis via Inhibiting IL-6/STAT3 Signaling Pathway. Journal of Ethnopharmacology, 283, Article ID: 114701. https://doi.org/10.1016/j.jep.2021.114701 |
